Yu Wu, Lei Zhao, Yufei Yang, Xinrong Xiang. "Venetoclax-based regimens are non-inferior to chemotherapy in core binding factor AML, including AML1-ETO." Blood (2025). https://doi.org/10.1182/blood-2025-6965